Αποτελέσματα Αναζήτησης
12 Σεπ 2023 · Section 2 examines how ADNI data have directly contributed to the development of AD therapies, describes important data harmonization efforts, outlines progress in the development of plasma biomarkers for clinical use, and reviews diagnostic and prognostic models.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD).
1 Ιουλ 2015 · This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. Methods. Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors. Results.
29 Σεπ 2023 · The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multi-site, multi-year, observational study, launched in 2004 by the National Institute on Aging (NIA) to develop and validate a broad range of biomarkers that will aid in facilitating successful clinical trials for the treatment of Alzheimer's disease (AD). 1 ADNI, led by its founder a...
The goals of the Alzheimer's Disease Neuroimaging Initiative (ADNI) are accomplished through the enrollment and longitudinal follow-up of cohorts of individuals with mild cognitive impairment (MCI) and mild Alzheimer's disease (AD), as well as cognitively normal older individuals.
Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020.
This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use.
